^
Association details:
| Biomarker: | GOPC-ROS1 G2032 |
|---|---|
| Cancer: | Lung Cancer |
| Drug: | Xalkori (crizotinib) (ALK inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Mutation profiling and treatment choosing of Chinese ROS1 positive advanced lung cancer patients.
Published date:
05/16/2018
Excerpt:
One patient with GOPC-ROS1 fusion accepted Crizotinib as first-line therapy for 19 months, and disease progressed due to ROS1 G2032 mutation, passed away after 3 months with Cabozantinib….the major therapy choice of Chinese ROS1+ advanced lung cancer patients.
